Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.

Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB; DISCOVER-2 Study Group.

Lancet. 2020 Apr 4;395(10230):1126-1136. doi: 10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13. Erratum in: Lancet. 2020 Apr 4;395(10230):1114.

PMID:
32178766
2.

Older adults on systemic treatment for psoriasis and risk of infection: a propensity score matched population-based study.

Schneeweiss MC, Perez-Chada L, Gottlieb AB, Merola J.

Br J Dermatol. 2020 Mar 11. doi: 10.1111/bjd.19028. [Epub ahead of print]

PMID:
32159850
3.

JOINT AAD-NPF GUIDELINES OF CARE FOR THE MANAGEMENT OF PSORIASIS WITH SYSTEMIC NON-BIOLOGICAL THERAPIES.

Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2020 Feb 28. pii: S0190-9622(20)30284-X. doi: 10.1016/j.jaad.2020.02.044. [Epub ahead of print]

PMID:
32119894
4.

Integrated Safety Analysis: Frequency of Urinary Tract Infections in Patients with Psoriasis Treated with Ixekizumab.

Smith SD, Conrad C, Ramharter M, Gottlieb AB, Patel H, Xu W, Riedl E, Schuster C.

J Am Acad Dermatol. 2020 Feb 21. pii: S0190-9622(20)30286-3. doi: 10.1016/j.jaad.2020.02.045. [Epub ahead of print] No abstract available.

5.

Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial.

Casseres RG, Prussick L, Zancanaro P, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Au SC, Alomran A, Abdat R, Abudu M, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D.

J Am Acad Dermatol. 2020 Feb 7. pii: S0190-9622(20)30209-7. doi: 10.1016/j.jaad.2020.02.005. [Epub ahead of print] No abstract available.

PMID:
32044410
6.

Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review.

Perez-Chada LM, Balak D, Cohen JM, Ogdie A, Merola JF, Gottlieb AB.

Expert Rev Clin Immunol. 2020 Mar;16(3):267-283. doi: 10.1080/1744666X.2020.1724090. Epub 2020 Feb 8.

PMID:
32037912
7.

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.

Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, Gottlieb AB, Assudani D, Bedford-Rice K, Coarse J, Ink B, McInnes IB.

Lancet. 2020 Feb 8;395(10222):427-440. doi: 10.1016/S0140-6736(19)33161-7.

PMID:
32035552
8.

Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials.

Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa AC, Combe B, Rech J, Zhu X, James D, Martin R, Ligozio G, Abrams K, Pricop L.

J Clin Rheumatol. 2020 Feb 3. doi: 10.1097/RHU.0000000000001302. [Epub ahead of print]

PMID:
32015257
9.

Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM).

Kornmehl H, Callis Duffin K, Salame N, Perez-Chada LM, Singh S, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW.

Dermatology. 2020 Jan 28:1-7. doi: 10.1159/000501582. [Epub ahead of print]

PMID:
31991410
10.

Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative.

Perez-Chada LM, Salame NF, Ford AR, Duffin KC, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW.

Am J Clin Dermatol. 2020 Jan 16. doi: 10.1007/s40257-019-00496-w. [Epub ahead of print] Review.

PMID:
31950353
11.

Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics.

Ritchlin CT, Stahle M, Poulin Y, Bagel J, Chakravarty SD, Kafka S, Srivastava B, Langholff W, Gottlieb AB.

BMC Rheumatol. 2019 Nov 28;3:52. doi: 10.1186/s41927-019-0094-3. eCollection 2019.

12.

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.

Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2020 Jan;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049. Epub 2019 Nov 5. Erratum in: J Am Acad Dermatol. 2020 Mar;82(3):574.

PMID:
31703821
13.

Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).

Lebwohl MG, Leonardi CL, Mehta NN, Gottlieb AB, Mendelsohn AM, Parno J, Rozzo SJ, Menter A.

J Am Acad Dermatol. 2020 Feb;82(2):519-522. doi: 10.1016/j.jaad.2019.09.042. Epub 2019 Sep 26. No abstract available.

14.

Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast.

Natsis NE, Merola JF, Weinberg JM, Wu JJ, Orbai AM, Bagel J, Gottlieb AB.

Am J Clin Dermatol. 2020 Feb;21(1):109-117. doi: 10.1007/s40257-019-00468-0.

PMID:
31452091
15.

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase 2 Trial.

Helliwell PS, Deodhar A, Gottlieb AB, Boehncke WH, Xu XL, Xu S, Wang Y, Hsia EC, Gladman DD, Ritchlin CT.

Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24046. [Epub ahead of print]

PMID:
31421033
16.

Clinical considerations for the management of psoriasis in women.

Gottlieb AB, Ryan C, Murase JE.

Int J Womens Dermatol. 2019 Apr 10;5(3):141-150. doi: 10.1016/j.ijwd.2019.04.021. eCollection 2019 Jul. Review.

17.

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.

Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Sep;81(3):775-804. doi: 10.1016/j.jaad.2019.04.042. Epub 2019 Jul 25. Erratum in: J Am Acad Dermatol. 2020 Mar;82(3):780.

PMID:
31351884
18.

Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.

Gottlieb AB, Kubanov A, van Doorn M, Sullivan J, Papp KA, You R, Regnault P, Frueh JA.

Br J Dermatol. 2020 Apr;182(4):889-899. doi: 10.1111/bjd.18331. Epub 2019 Dec 15.

PMID:
31286480
19.

Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials.

Perez-Chada LM, Gottlieb AB, Cohen J, Mease P, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF.

J Am Acad Dermatol. 2020 Jan;82(1):54-61. doi: 10.1016/j.jaad.2019.05.075. Epub 2019 Jun 1.

PMID:
31163240
20.

Report of the Skin Research Workgroups from the GRAPPA 2018 Annual Meeting.

Perez-Chada LM, Merola JF, Armstrong AW, Gottlieb AB.

J Rheumatol Suppl. 2019 Jun;95:28-32. doi: 10.3899/jrheum.190124.

PMID:
31154401
21.

Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Callis Duffin K, Gladman DD, Gottlieb AB, Goel N.

J Rheumatol Suppl. 2019 Jun;95:1-3. doi: 10.3899/jrheum.190112.

PMID:
31154397
22.
23.

Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review

Kahn JS, Casseres RG, Her MJ, Dumont N, Gottlieb AB, Rosmarin D.

J Drugs Dermatol. 2019 Apr 1;18(4). pii: S1545961619P0387X.

PMID:
31013012
24.

Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials.

McInnes IB, Puig L, Gottlieb AB, Ritchlin CT, Song M, You Y, Kafka S, Morgan GJ, Rahman P, Kavanaugh A; PSUMMIT 1 and 2 Study Groups.

J Rheumatol. 2019 Nov;46(11):1458-1461. doi: 10.3899/jrheum.180792. Epub 2019 Apr 1.

PMID:
30936281
25.

Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry.

Kavanaugh A, Papp K, Gottlieb AB, de Jong EMGJ, Chakravarty SD, Kafka S, Langholff W, Farahi K, Srivastava B, Scher JU.

BMC Rheumatol. 2018 Sep 29;2:29. doi: 10.1186/s41927-018-0034-7. eCollection 2018.

26.

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y.

J Am Acad Dermatol. 2019 Jul;81(1):76-90. doi: 10.1016/j.jaad.2019.02.067. Epub 2019 Mar 11. Review.

PMID:
30872156
27.

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y.

J Am Acad Dermatol. 2019 Jul;81(1):91-101. doi: 10.1016/j.jaad.2019.02.068. Epub 2019 Mar 11. Review.

PMID:
30872149
28.

Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.

Prussick L, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Abdat R, Alomran A, Zancanaro P, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D.

Br J Dermatol. 2019 Sep;181(3):609-611. doi: 10.1111/bjd.17822. Epub 2019 May 12. No abstract available.

PMID:
30801662
29.

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13. Review.

PMID:
30772098
30.

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13. Review.

PMID:
30772097
31.

Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.

Thorlacius L, Garg A, Riis PT, Nielsen SM, Bettoli V, Ingram JR, Del Marmol V, Matusiak L, Pascual JC, Revuz J, Sartorius K, Tzellos T, van der Zee HH, Zouboulis CC, Saunte DM, Gottlieb AB, Christensen R, Jemec GBE.

Br J Dermatol. 2019 Sep;181(3):483-491. doi: 10.1111/bjd.17716. Epub 2019 Jun 6.

PMID:
30724351
32.

Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventions.

Prussick L, Tonelli S, Gottlieb AB, Joshipura D, Alomran A, Zancanaro P, Courtney Kachuk RN, Dumont N, Rosmarin D.

J Dermatolog Treat. 2019 Nov;30(7):708-713. doi: 10.1080/09546634.2018.1562536. Epub 2019 Jun 24.

PMID:
30582391
33.

Clinical Goals and Barriers to Effective Psoriasis Care.

Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, Cohen AD, de la Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, Iversen L, Kleyn CE, Leonardi CL, Lynde CW, Ryan C, Theng CT, Valenzuela F, Vender R, Wu JJ, Young HS, Kimball AB.

Dermatol Ther (Heidelb). 2019 Mar;9(1):5-18. doi: 10.1007/s13555-018-0279-5. Epub 2018 Dec 21.

34.

Bimekizumab for the treatment of psoriatic disease.

Natsis NE, Gottlieb AB.

Expert Opin Biol Ther. 2018 Dec;18(12):1193-1197. doi: 10.1080/14712598.2018.1538351. Epub 2018 Oct 23. Review.

PMID:
30332893
35.

Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.

Coates LC, Gottlieb AB, Merola JF, Boone C, Szumski A, Chhabra A.

J Rheumatol. 2019 Feb;46(2):160-165. doi: 10.3899/jrheum.180249. Epub 2018 Oct 15.

PMID:
30323006
36.
37.

Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.

Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB.

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):546-552. doi: 10.1111/jdv.15258. Epub 2018 Oct 14.

38.

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.

Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ.

Clin Rheumatol. 2018 Dec;37(12):3285-3296. doi: 10.1007/s10067-018-4227-7. Epub 2018 Sep 6. Erratum in: Clin Rheumatol. 2018 Oct 11;:.

PMID:
30191421
39.

Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.

Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R.

Br J Dermatol. 2019 Jan;180(1):67-75. doi: 10.1111/bjd.17149. Epub 2018 Oct 10.

PMID:
30188571
40.

Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative.

Perez-Chada LM, Cohen JM, Gottlieb AB, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF.

Arch Dermatol Res. 2018 Nov;310(9):701-710. doi: 10.1007/s00403-018-1855-3. Epub 2018 Aug 25.

PMID:
30167814
41.

Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis.

Salame N, Perez-Chada LM, Singh S, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW.

Dermatology. 2018;234(5-6):157-165. doi: 10.1159/000490413. Epub 2018 Aug 17.

42.

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.

Rheumatology (Oxford). 2018 Oct 1;57(10):1777-1788. doi: 10.1093/rheumatology/key161.

43.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A.

J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19. doi: 10.1016/j.jaad.2018.06.027. Epub 2018 Jun 19.

PMID:
29928910
44.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, Barchuk W, Xu XL, Hsia EC; CNTO1959PSA2001 Study Group.

Lancet. 2018 Jun 2;391(10136):2213-2224. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1.

PMID:
29893222
45.

Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.

Callis Duffin K, Merola JF, Christensen R, Latella J, Garg A, Gottlieb AB, Armstrong AW.

JAMA Dermatol. 2018 Oct 1;154(10):1137-1144. doi: 10.1001/jamadermatol.2018.1165.

46.

Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting.

Gottlieb AB, Coates LC, van Mens LJJ, Armstrong AW, Merola JF.

J Rheumatol Suppl. 2018 Jun;94:40-43. doi: 10.3899/jrheum.180137.

PMID:
29858353
47.

Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Helliwell PS, Gladman DD, Gottlieb AB.

J Rheumatol Suppl. 2018 Jun;94:1-3. doi: 10.3899/jrheum.180129.

PMID:
29858345
48.

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.

Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A; IXORA-Q Study Group.

Br J Dermatol. 2018 Oct;179(4):844-852. doi: 10.1111/bjd.16736. Epub 2018 Jul 22.

PMID:
29747232
49.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).

Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K.

J Am Acad Dermatol. 2018 Aug;79(2):302-314.e6. doi: 10.1016/j.jaad.2018.04.012. Epub 2018 Apr 13.

50.

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.

Thorlacius L, Ingram JR, Villumsen B, Esmann S, Kirby JS, Gottlieb AB, Merola JF, Dellavalle R, Nielsen SM, Christensen R, Garg A, Jemec GBE; HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).

Br J Dermatol. 2018 Sep;179(3):642-650. doi: 10.1111/bjd.16672. Epub 2018 Jul 5.

Supplemental Content

Loading ...
Support Center